

PRODUCT SPECIFICATION SHEET

Dermato Supplement (MS013)

Intended Use

An antibiotic supplement recommended for the selective isolation of pathogenic dermatophytes.

Composition

Each vial contains the following:

*Ingredients	Concentration
Cycloheximide	250.00 mg
Chlortetracycline	50.00 mg
Gentamicin	50.00 mg

Directions

- 1. One vial is sufficient for 500ml medium.
- 2. Rehydrate the content of 1vial aseptically with 5 ml of 50% v/v acetone.
- 3. Mix well and aseptically add it to 500 ml of sterile, molten D.T.M. Agar Base (DM079).
- 4. Mix gently and pour into sterile petri plates.

Storage and Shelf Life

Store at 2 - 8°C. Use before expiry date on the label.

Note: * Not for medicinal use

Further Information

For further information please contact your local MICROMASTER Representative.



MICROMASTER LABORATORIES PRIVATE LIMITED

MS013PSS, QAD/FR/024, Rev. 00/01.01.2018

Unit 38/39, Kalpataru Industrial Estate, Off G.B. Road, Near 'R-Mall', Thane (W) - 400607. M.S. INDIA.

Ph: +91-22-25895505, 4760, 4681. Cell: 9320126789.

Email: micromaster@micromasterlab.com











PRODUCT SPECIFICATION SHEET

Checked By	Approved By
Sundak 21.2018	1000/2018
Head Quality Control	Head Quality Assurance
	Jusdak 01.01.2018

Disclaimer:

All Products conform exclusively to the information contained in this and other related Micromaster Publications. Users must ensure that the product(s) is appropriate for their application, prior to use. The information published in this publication is based on research and development work carried out in our laboratory and is to the best of our knowledge true and accurate. Micromaster Laboratories Pvt Ltd reserves the right to make changes to specifications and information related to the products at any time. Products are intended for laboratory, diagnostic, research or further manufacturing use only and not for human or animal or therapeutic use, unless otherwise specified. Statements included herein should not be considered as a warranty of any kind, expressed or implied, and no liability is accepted for infringement of any patents.







